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Background: Acquired dysfunctional immunity in cirrhosis predisposes patients to
frequent bacterial infections, especially spontaneous bacterial peritonitis (SBP), leading to
systemic inflammation that is associated with poor outcome. But systemic inflammation
can also be found in the absence of a confirmed infection. Detection of bacterial DNA
has been investigated as a marker of SBP and as a predictor of prognosis. Data is,
however, contradictory. Here we investigated whether levels of IL-6 and IL-8 putatively
produced by myeloid cells in ascites are associated with systemic inflammation and
whether inflammation depends on the presence of specific bacterial DNA.
Methods and Materials: We enrolled 33 patients with decompensated liver cirrhosis
from whom we collected paired samples of blood and ascites. IL-6 and IL-8 were
measured in serum samples of all patients using ELISA. In a subset of 10 representative
patients, bacterial DNA was extracted from ascites and whole blood, followed by 16S
rRNA gene amplicon sequencing.
Results: There were significantly higher levels of IL-6 in ascites fluid compared
to blood samples in all patients. Interestingly, IL-6 levels in blood correlated
tightly with disease severity and surrogates of systemic inflammation, while
IL-6 levels in ascites did not. Moreover, patients with higher blood CRP levels
showed greater SBP prevalence compared to patients with lower levels, despite
similar positive culture results. Bacterial richness was also significantly higher in
ascites compared to the corresponding patient blood. We identified differences
in microbial composition and diversity between ascites and blood, but no
tight relationship with surrogates of systemic inflammation could be observed.
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Discussion: In decompensated cirrhosis, markers of systemic inflammation and
microbiota composition seem to be dysregulated in ascites and blood. While a
relationship between systemic inflammation and microbiota composition seems to exist
in blood, this is not the case for ascites in our hands. These data may suggest
compartmentalization of the immune response and interaction of the latter with the
microbiota especially in the blood compartment.
Keywords: microbiome, systemic inflammation, myeloid cells, cirrhosis, ascites, cytokines, acute-on-chronic liver
failure
INTRODUCTION
Acquired dysfunctional immunity in cirrhosis predisposes
patients to frequent bacterial infections contributing to disease
progression and may lead to the development of acute-on-
chronic liver failure (ACLF) (1). Especially, spontaneous bacterial
peritonitis (SBP) is one of the most frequent infections in
cirrhosis and therefore a trigger for ACLF (2). Interestingly, SBP
is defined by the number of granulocytes in ascites and not by
cultural detection of bacteria (3). This is because many patients
with SBP show negative bacterial cultivation from ascites, while
in many other patients, viable bacteria can be cultivated in the
absence of peritonitis, so-called bacterascites (3). Lack of bacterial
cultivation in the presence of SBP can be explained by the concept
of dormant microbiota, meaning that bacteria can reside inside
circulating and resident immune cells but cannot be cultured and
hence detected (4).
The source of infection, especially in the case of SBP,
is suspected to be bacterial translocation from the gut (2),
which is facilitated by impaired intestinal defense and increased
intestinal permeability, processes which are correlated with the
stage of cirrhosis (5). Not only viable bacteria (1, 6), but
also bacterial components broadly termed pathogen-associated
molecular patterns (PAMPs) may induce an immune response
and aggravate systemic inflammation (2). As a consequence,
the presence of circulating bacterial DNA reflects bacterial
translocation in cirrhosis. However, the relationship of bacterial
DNAwith systemic inflammation is still controversially discussed
(7, 8). PAMP-associated immune response requires recognition
by innate immune cells and is reflected by synthesis and
secretion of cytokines. Especially levels of the cytokines IL-
6 and IL-8 are closely related to ACLF and clinical outcome
(9). At the same time, the antibacterial capacity of myeloid
cells and myelopoiesis is impaired during decompensation
and ACLF (10, 11). Interestingly, these effects are not only
induced by PAMPs (deriving from pathogens), but in general
by bacterial-derived molecules, so-called microbe-associated
molecular patterns (MAMPs).
Recent data from our group suggest that specific circulating
bacteria or MAMPs in blood are associated with myeloid cell
dysregulation and systemic inflammation (12). Therefore, a
specific microbial DNA may be more crucial than just detecting
any bacterial DNA in circulation. In ascites, the detection of
bacterial DNA in ascites does not seem to correlate with SBP or
clinical signs of infection (13). Therefore, the question remains,
whether specific bacteria in ascites lead to myeloid cell activation
with subsequent cytokine release and a systemic inflammatory
response. To address this question, we investigated whether the
representative cytokine (IL-6, IL-8) levels produced by myeloid
cells in ascites reflect systemic inflammation. Moreover, we
compared the levels of cytokines in paired ascites and blood
samples, together with the general bacterial composition and
specific species abundances of the microbiota estimated by 16S
ribosomal RNA gene sequencing. Our study focused not only on
common pathogens but also on the role of MAMPs in activating
myeloid cells of the innate immune response. We hypothesize
that DNA from specific bacterial species, but not any bacterial
DNA, induces an inflammatory response in cirrhotic patients.
MATERIALS AND METHODS
Patient Recruitment and Sample Collection
Ascites and blood were collected in 33 cirrhotic patients
scheduled for paracentesis. Paracentesis was performed by
international standards (14). The study was performed in
accordance with the declaration of Helsinki and approved by the
local ethics committee at the University of Bonn (Nr. 121/14).
Patients gave their written informed consent.
Microbiological Analysis
Microbiological culture of blood and ascites was performed at
the clinical microbiology department at the University of Bonn
in accordance with Microbiology Procedures Quality Standards
of the German Society for Hygiene and Microbiology (15, 16).
Ten milliliters of peripheral whole blood or ascitic fluid were
transferred into aerobic, anaerobic and fungal blood culture
bottles and incubated for up to 5 days using the Bactex FX blood
culture system as described previously (17). SBP was diagnosed
based on a leucocyte count in ascites >250/µl (3).
Enzyme-Linked Immunosorbent Assay
Ascites and peripheral blood samples (serum, EDTA-plasma
and whole-blood) were collected during paracentesis and
stored immediately at −80◦C until further use. Enzyme-linked
immunosorbent assay for cytokines IL-6 and IL-8 (DY206 and
DY208, respectively; R&D Systems Inc., Minneapolis, MN, USA)
were performed according to the manufacturer’s protocols. All
samples were measured in duplicates.
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16S Ribosomal RNA Gene Sequencing
For extraction of total DNA, 100µl of whole blood or ascitic fluid
were used. Samples were mechanically lysed two times for 30 s at
20Hz in a bead beater (TissueLyser, Qiagen, Hilden, Germany)
with 0.1mm glass beads (MoBio, CA, USA). DNA extraction was
performed using the NucleoSpin Blood Kit (Macherey-Nagel,
Düren, Germany). Quality and quantity of extracted nucleic
acids were controlled by gel electrophoresis. 16S rRNA gene
V3-V4 hypervariable regions were amplified and quantified by
qPCR, and sequenced using MiSeq technology (Illumina, San
Diego, CA, USA) as described previously producing 2 × 300 bp
paired-end reads (18, 19).
Bioinformatics and Statistical Analysis
Paired-ends reads were processed in DADA2 version 1.6.0
(20) using the following parameters: “trimLeft = 10,
truncLen = (260;230), maxN = 0, maxEE = (2,5),
minOverlap = 20, maxMismatch = 1, pool=TRUE.” The
resulting output was an amplicon sequence variant (ASV) table.
The ASVs were mapped against SILVA database (21) release 128.
Data analysis was performed in R version 3.5, using phyloseq
package (22) version 1.24.2. Genus level relative abundances
were generated by combining ASVs annotated with the same
genus using phyloseq package. The alpha-diversity measures
were calculated based on rarefied data at 6,000 reads/sample.
Significant differences in alpha-diversity between ascites and
blood samples as well as between samples with different
inflammation status were determined using t-test.
Beta-diversity was calculated using unweighted and weighted
UniFrac measures. Effects of different factors on beta-diversity
were determined using Adonis Permutational Multivariate
Analysis of Variance (PERMANOVA) test from the vegan
package (23) version 2.5.2. For differential abundance analysis,
we chose a t-test based on the evaluation using DAtest package
(24) version 2.7.11, which showed that, compared with different
statistical tests, t-test has the highest area under the curve
(AUC = 0.608) while keeping the false discovery rate (FDR)
under 0.05.
Statistical analysis of patient characteristics and clinical
measures was performed using SPSS version 24 (IBM, Armonk,
NY) andMann–Whitney test for metric variables and Chi-square
test for nominal variables. Receiver operator characteristic curve
analysis was used to define a cut-off for CRP and divide the cohort
into one group with low CRP profile and one group with high
CRP profile. P-values were adjusted for multiple testing using
Benjamini–Hochberg FDR procedure. An FDR-adjusted P-value
below 0.05 was considered statistically significant.
RESULTS
General Description of the Cohort
General characteristics of the patients are summarized in
Table 1. The cohort consists of patients with decompensated
liver cirrhosis as reflected by the model for end-stage liver
disease (MELD) and Child-Pugh (CHILD) scores, which assess
severity of liver disease, prognosis and mortality. The median
MELD score of 15 represents a value at which patients
would benefit from liver transplantation. The median CHILD
score of 10 is associated with a 1-year survival below 50%.
Seventy-two percent of the patients (24/33) showed ACLF
at baseline.
The median C-reactive protein (CRP) level of 48.8 mg/l in
the blood were compatible with bacterial infections (upper limit
of normal 5 mg/l), together with findings of SBP in 21% of
the patients (Table 1). CRP performed well to detect SBP using
receiver operator characteristic curve analysis (AUC = 0.901,
P ≤ 0.001). In blood cultures, we detected members of the
bacterial genera Enterococcus, Escherichia, Sporosarcina, and
Staphylococcus in five patients. Additionally, we detectedCandida
spp. in blood culture of one patient. In ascites, we detected the
genera Enterococcus, Serratia, and Staphylococcus in five patients
and Candida spp. in one patient. None of the patients presented
with cultural evidence of bacteria in both, blood and ascites.
There was also evidence of systemic inflammation with
elevated levels of cytokines IL-6 (and IL-8, although not
statistically significant), which are mainly produced by myeloid
cells. The median levels assessed by ELISA assays were 33.53
and 68.78 pg/ml, respectively (Table 1). Reported mean levels in
healthy individuals are 1.46 and 12.9 pg/ml, respectively, assessed
by the same technique (25, 26). Ascites fluid showed higher
median levels of both cytokines, with an almost 20-fold increase
of median IL-6 levels in ascites compared to blood from the
same patient.
Differences in Patients With Systemic
Inflammation
In order to decipher the role of systemic inflammation, we
divided the cohort into two groups according to their CRP
level. A cut-off of 25 mg/l (sensitivity = 1.0, specificity = 0.54
for detection of SBP) was used to divide the cohort into 12
patients with a low CRP profile and 21 patients with a high
CRP profile. Patients with the high CRP profile showed higher
MELD, CHILD, and Chronic Liver Failure Consortium (CLIF-
C)-ACLF scores (Table 1; P = 0.06, P = 0.03, and P = 0.002,
respectively). SBP was detected in 50% of the patients (7 out
of 14) with the high CRP profile, but in none of 12 patients
with the low CRP profile (P = 0.02). Therefore, the positive
predictive value, the probability for patients with high CRP
profile to have SBP, is 35%. In contrast, the negative predictive
value, the chance for patients with low CRP profile to not have
SBP, is 100%. A high negative predictive value in this regards
is extremely important since CRP level may be elevated also
in absence of infection. Furthermore, patients with the high
CRP profile showed a significant increase in blood granulocyte
counts (P = 0.001), leucocyte counts (P = 0.004), and IL-
6 levels (P = 0.002). However, there was no difference in
ascitic cytokine levels between these two groups (Table 1).
Similarly, IL-6 levels in blood strongly correlate with MELD,
CHILD score, and CLIF-C-ACLF score and surrogate markers
of systemic inflammation (leucocytes and CRP). However, blood
IL-8 levels only slightly reflected disease stage and did not
correlate significantly withmarkers of inflammation (Figure 1A).
Even though median cytokine levels were higher in ascites than
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TABLE 1 | Patient characteristics.
Parameters All (n = 33) Low CRP profile
(n = 12)
High CRP profile
(n = 21)
P
General characteristics Sex (male/female) 23/10 8/4 15/6 0.78
Age, years 57 (33–105) 53.5 (40.0–75.0) 60.0 (33.0–105.0) 0.19
Etiology of cirrhosis (alcohol/viral/other) 18/8/7 8/4/0 10/4/7 0.08
MELD 15.71 (3.66–39.65) 13.87 (9.79–38.25) 20.50
(3.66–39.65)
0.06
CHILD 10 (7–15) 9 (7–13) 10 (7–15) 0.03
ACLF (no/yes) 9/24 5/7 4/17 0.16
CLIF-C-ACLF 57 (39–84) 44 (39–57) 60 (47–84) 0.002
Esophageal varices (absent/small/large) 14/8/11 6/2/4 8/6/7 0.38
Hepatic encephalopathy (absent/grade 1/grade
2/grade 3/grade 4)
22/4/3/2/2 11/1/0/0/0 11/3/3/2/2 0.20
Hepatorenal syndrome (no/yes) 14/19 6/6 8/13 0.51
Spontaneous bacterial peritonitis (no/yes) 26/7 12/0 14/7 0.02
Blood culture (negative/positive/NA) 12/6/15 4/2/6 8/4/9 1.00
Ascites culture (negative/positive/NA) 24/6/3 11/1/0 13/5/3 0.19
Laboratory blood Creatinine [mg/dl] 1.40 (0.57–4.68) 1.30 (0.57–2.59) 1.58 (0.86–4.68) 0.10
Platelets [106/l] 120 (7–685) 108 (38–235) 120 (7–685) 0.84
INR 1.4 (1.0–5.5) 1.35 (1.00–2.10) 1.40 (1.00–5.50) 0.78
Bilirubin [mg/dl] 2.08 (0.37–45.21) 1.92 (0.75–45.21) 3.20 (0.37–35.41) 0.81
GGT [U/l] 152 (26–1,139) 139 (33–585) 181 (26–1,139) 0.76
ALT [U/l] 32 (8–1,050) 49.5 (17.0–269.0) 30.0 (8.0–1050.0) 0.75
CRP [mg/l] 48.8 (5.7–205.0) 13.55 (5.70–22.20) 60.20
(27.60–205.00)
0.000
Granulocytes [106/l] 100 (10–1,070) 40 (10–170) 230 (10–1,070) 0.001
Leucocytes [106/l] 9.81 (3.34–31.18) 7.01 (3.60–22.20) 15.09
(3.34–31.18)
0.004
Monocytes [103/l] 1.09 (0.24–12.80) 0.86 (0.24–1.90) 1.13 (0.26–12.80) 0.43
IL6 [pg/ml] 33.53 (3.63–684.84) 10.97 (3.95–236.71) 83.42
(3.63–684.84)
0.002
IL8 [pg/ml] 68.78 (5.67–752.26) 43.76 (15.54–752.26) 77.84
(7.87–1487.36)
0.46
Laboratory ascites Protein [g/l] 10 (1–44) 9.5 (4.0–19.0) 10.0 (1.0–44.0) 0.65
Granulocytes [106/l] 48 (2–2,333) 48 (7–250) 48 (2–2,333) 0.97
Leucocytes [103/l] 256 (11–3,031) 467 (52–887) 218 (11–3,031) 0.40
Lymphocytes/Monocytes [103/l] 127 (5–740) 300 (39–740) 127 (5–698) 0.15
IL6 [pg/ml] 642.67 (7.87–1487.36) 596.15
(109.56–1226.54)
653.58
(7.87–1487.36)
0.45
IL8 [pg/ml] 83.75 (10.91–988.56) 44.91 (15.17–277.70) 95.55
(10.90–988.56)
0.15
Data are medians and (ranges). The results of Mann–Whitney test for metric variables and Chi-square test for nominal variables comparing patients with low CRP profile to those with
high CRP profile are shown with P–value (significantly different comparisons are marked in bold).
in blood (Figure 1B), ascitic cytokine levels reflected neither
disease severity nor systemic inflammation (Figures 1A,C).
Therefore, ascites cytokine levels did not seem to be affected
by systemic inflammation or by the presence of SBP, which was
diagnosed in one third of the patients with the high CRP profile
(Figure 1C).
The rate of positive blood cultures was identical in
patients with the low and high CRP profile. There were
three positive blood and three positive ascites cultures in
patients with a high CRP against two positive blood and
one positive ascites cultures in the patients with lower
CRP values.
Characterizing the Microbiome in Ascites
and Blood
We selected a subset of 10 representative patients (accounting for
etiology and inflammation markers in ascites) from the whole
cohort and performed 16S rRNA gene sequencing of ascites
and blood to identify differences in microbial composition and
diversity between ascites and blood. These 10 patients were also
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TABLE 2 | Patient characteristics for the subpopulation in which 16S rRNA gene amplicon sequencing was performed in blood and ascites.
Parameters Low CRP profile
(n = 6)
High CRP profile
(n = 4)
P
General characteristics Sex (male/female) 5/1 2/2 0.26
Age, years 52.5 (40.0–67.0) 56.0 (33–76) 0.76
Etiology of cirrhosis (alcohol/viral/other) 5/1/0 3/0/1 0.34
MELD 10.26 (9.79–38.25) 18.72 (11.21–24.16) 0.17
CHILD 9.0 (8.0–13.0) 9.5 (8.0–10.0) 0.91
ACLF (no/yes) 4/2 1/3 0.20
Esophageal varices (absent/small/large) 3/0/3 2/1/1 0.17
Hepatic encephalopathy (absent/grade 1/grade
2/grade 3/grade 4)
5/1/0/0 3/1/0/0 0.34
Hepatorenal syndrome (no/yes) 4/2 2/2 0.60
Spontaneous bacterial peritonitis (no/yes) 6/0 3/1 0.20
Blood culture (negative/positive/NA) 2/1/3 0/1/3 0.25
Ascites culture (negative/positive/NA) 6/0/0 3/1/0 0.20
Laboratory blood Creatinine [mg/dl] 0.98 (0.57–2.59) 2.27 (1.07–4.68) 0.17
Platelets [106/l] 69.5 (38.0–235.0) 191.5 (123.5–237.5) 0.26
INR 1.35 (1.00–2.10) 1.20 (1.00–1.20) 0.47
Bilirubin [mg/dl] 2.78 (0.75–45.21) 1.54 (0.73–7.97) 0.61
GGT [U/l] 226.0 (152.0–585.0) 149.5 (78.0–1139.0) 0.47
CRP [mg/l] 14.4 (5.7–22.2) 94.6 (27.6–205.0) 0.01
Leucocytes [106/l] 5.33 (3.60–9.07) 7.37 (6.59–17.30) 0.07
Monocytes [103/l] 0.57 (0.24–0.87) 1.10 (0.73–1.17) 0.10
IL6 [pg/ml] 8.32 (3.95–236.71) 81.66 (19.94–97.29) 0.39
IL8 [pg/ml] 41.80 (15.54–752.26) 66.61 (25.08–192.48) 0.61
Laboratory ascites Protein [g/l] 8 (5–17) 21 (10–44) 0.11
Granulocytes [106/l] 18.5 (7–250) 24.0 (10.0–117.0) 0.91
Leucocytes [103/l] 130.5 (52.0–824.0) 163.0 (47.0–480.0) 0.61
Lymphocytes/Monocytes [103/l] 120.0 (39.0–740.0) 139.5 (37.0–363.0) 0.61
IL6 [pg/ml] 757.19
(109.56–1226.54)
529.64 (7.87–816.83) 0.35
IL8 [pg/ml] 29.93 (17.46–277.70) 116.82 (43.12–224.85) 0.17
Data are medians and (ranges). The results of Mann–Whitney test for metric variables and Chi-square test for nominal variables comparing patients with low CRP profile to those with
high CRP profile are shown with P-value (significantly different comparisons are marked in bold).
divided into two groups based on CRP levels (n= 4 for high CRP
profile and n= 6 for low CRP profile, see Table 2). Their disease
profiles with regard to stage of liver cirrhosis and inflammatory
markers in blood were comparable to those of the respective
subgroups and also of the whole cohort.
Microbiota compositions at the phylum level were in line
with previously reported bacterial compositions of ascites
(27) and peripheral blood (12). The most abundant phylum
detected in ascites samples was Proteobacteria (mean relative
abundance 77.7%), followed by Firmicutes (9.4%), Actinobacteria
(7.9%), Bacteroidetes (3.9%), and Gemmatimonadetes (0.6%)
(Figure 2). The phylum composition was slightly different
in the blood samples, with Proteobacteria accounting for
87.4% on average, while Actinobacteria, Firmicutes, and
Bacteroidetes accounted for small proportions (5.3, 3.7, and
3.5, respectively; Figure 2). We identified 53 bacterial families
in ascites and 48 families in blood samples. Among these,
we found a set of six core families detected in all samples in
both compartments: Pseudomonadaceae, Oxalobacteriaceae,
Neisseriaceae, Enterobacteriaceae, Sphingomonadaceae, and
Moraxellaceae. These results were in line with previous
studies that reported an increase in potentially pathogenic
families such as Enterobacteriaceae on the gut microbiome
of liver patients and as well a high prevalence in ascites
samples (28).
We identified 97 bacterial genera from ascites and 89 genera
from blood (Figure S2). There were no statistical significant
differences between the microbiota compositions of ascites and
blood samples at phylum level. At genus level, alpha-diversity
indices, such as richness (number of observed genera in a sample)
and Shannon diversity (richness as well as evenness of genera in
a sample), showed that the ascites microbiome was significantly
more diverse than the peripheral blood microbiome (P < 0.01;
Figure 3A).
Translocation of the gut microbiota into the circulatory
system and into ascites is increasingly recognized as a driver
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FIGURE 1 | Pro-inflammatory cytokines. (A) Correlation of clinical markers for disease progression and systemic inflammation with cytokines IL-6 and IL-8 in blood
and ascites. (B) Comparison between cytokines levels in ascites and peripheral blood. (C) Comparison between cytokines levels in ascites and peripheral blood under
different systemic inflammation status (low CRP profile vs. high CRP profile).
of complication in advanced liver disease (27, 29). As we
showed above, the levels of pro-inflammatory cytokines (IL-6
and IL-8) were higher in ascites compared to blood, suggesting
different drivers of inflammation. To determine the relation of
the microbiota with cytokine levels and systemic inflammation,
we investigated the differences in the microbiome composition
of ascites and blood samples, in patients with low and high CRP
levels. CRP levels did not appear to affect microbiota diversity of
ascites or blood samples (Figure 3B).
Distinct Bacterial Signatures of Ascites
and Blood Microbiome
To study the variation in the microbial structure between
ascites and peripheral blood samples, we used unweighted
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FIGURE 2 | Average microbiome phylum composition in ascites and blood
samples (n = 10 each).
and weighted UniFrac metrics (30) as measures of the beta-
diversity. Unweighted UniFrac uses a phylogenetic tree taking
into account only the phylogenetic affiliation of members
to evaluate the community structure and diversity, while
weighted UniFrac additionally considers the relative abundance
of the members of the community. Both measures clearly
separated ascites from blood samples (Figure 4). The sampling
compartment explained 11% of the variance in beta-diversity
when using unweighted UniFrac metric (PERMANOVA test,
P = 0.006), whereas it explained 21.2% of the variance when
using weighted UniFrac metric (PERMANOVA test, P = 0.001).
Additionally, the first principal coordinate (PC1) of microbiome
beta-diversity explained 20.4% of the variance in the samples
under unweighted UniFrac metric, whereas it explained 34%
of the variance in the samples under weighted UniFrac metric
(Figure 4).
We then investigated specific bacterial signatures that
differentiated ascites from peripheral blood samples. We used
DAtest (24) to select the most suitable statistical method to
identify differentially abundant bacteria. Compared with other
statistical methods evaluated by DAtest, t-test had the highest
power to distinguish between two simulated sample groups based
on our cohort, while keeping the false discovery rate of simulated
differential taxa under 0.05. Therefore, we performed t-tests
between the ascites and blood microbiomes using the relative
abundances of 99 genera. We found that Janthinobacterium,
Serratia, and Rugamonas were significantly enriched in ascites,
while Escherichia/Shigella and Pseudomonas were enriched in
blood (Figure 5, Table 3). These findings were in concordance
with our cultivation results, where Serratiawas detected in ascites
culture and Escherichia in peripheral blood.
Since the presence of bacteria in blood is generally associated
with systemic inflammation, we investigated whether there
were differences in the bacterial composition of patients
with systemic inflammation (high CRP levels, n = 4) and
patients without systemic inflammation (low CRP levels,
n = 6). There was no significant difference between groups,
potentially due to limited sample size. We then examined the
5 bacterial genera that were significantly different between
ascites and blood samples to determine their relationship
with systemic inflammation. Although there were no
statistically significant differences between the samples with
and without systemic inflammation, Escherichia/Shigella and
Janthinobacterium were more abundant in patients with
elevated systemic inflammation, both in ascites and blood
samples, while Pseudomonas and Serratia were increased
only in the ascites samples with systemic inflammation
(Figure S1).
DISCUSSION
The present study demonstrates that the levels of inflammatory
cytokines and microbial richness are significantly higher in
ascites of patients with decompensated cirrhosis than in their
blood compartment. Neither the levels of cytokines nor the
overall abundance of bacterial DNA nor microbial richness
seemed to be related to the extent of systemic inflammation in
these patients.
These findings are particularly striking, since the cell
count in circulating blood is several fold higher than in
ascites. Still, the levels of inflammatory cytokines were several
fold reduced in blood compared to ascites. Moreover, the
relationship between the surrogates of systemic inflammation
(e.g., leucocyte count, CRP) and severity scores of liver
cirrhosis were correlated with the levels of blood cytokines,
but no relationship was detected in the same patients
in ascites.
A recent study described the role of alcohol consumption for
circulating microbiome composition and associated metabolic
functions. Even though leucocyte count and endotoxemia
increased with the severity of disease in this study, soluble
CD14, as a marker for monocyte activation, decreased in severe
alcoholic hepatitis underlining the dysregulation of the immune
response (31).
Overall, these results may suggest a dysregulation in myeloid
cell function in cirrhosis with an excess of cytokine synthesis in
ascites. This does, however, not result in at least the two main
markers of systemic inflammation investigated here. Although
rather descriptive, our study suggests compartmentalization
of the immune response in this setting. This compartmental
dysregulation may occur as a response to MAMPs, e.g.,
bacterial DNA.
The reason for this compartmentalization of the immune
response remains elusive. Granulocytes, as one of the main
producers of cytokines, besides macrophages and monocytes,
but crucial for the diagnosis of SBP, were similar or lower in
ascites samples than blood samples, although levels of IL-6
and IL-8 were many times higher in ascites. This suggests
an external source of these cytokines and inflammation in
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FIGURE 3 | (A) Alpha diversity indices at genus level. Ascites microbiota has higher richness and diversity compared to peripheral blood microbiome. (B) Alpha
diversity indices under different systemic inflammation status. The inflammation status does not affect the microbial diversity of the ascites or blood samples.
ascites. Bacterial translocation from the gut is suspected to
be the primary source of infection in SBP (2). However,
bacteria not associated to the gut can also be found in
ascites, suggesting other additional sources of infection (27).
Bacterial translocation has been associated with impaired
immune response and decompensation of liver cirrhosis, but
the efforts to elaborate simple biomarkers such as detection
and cut-off levels of bacterial DNA have shown discrepant
results. Such discrepancies highlight that the relationship
of presence or amount of bacterial DNA is not a strong
predictor for decompensation and systemic inflammation
in these patients, and probably also does not explain
compartmentalization of the immune response. However,
recent studies show an association of bacterial DNA levels in
ascites and survival (32, 33).
Therefore, we have characterized the microbiome of matched
ascites and blood samples from patients with decompensated
liver cirrhosis. While ascites and blood harbored the same
phyla with marginally different proportions, they showed
distinct compositions at genus level. Genus alpha-diversity
represented by richness and Shannon’s diversity was significantly
higher in ascites than in blood. Depending on the choice
of the beta-diversity measure, 11% (unweighted UniFrac), or
21.2% (weighted UniFrac) of the variance in beta-diversity
was dependent on the sampling compartment. These results
suggest that the phylogeny of the members as well as
their relative abundance have a significant yet cumulative
effect in explaining the differences between ascites and blood
microbial communities.
Culture-positive organisms per se do not seem to trigger
systemic inflammation assessed by two representative cytokines
(9) in patients with cirrhosis as demonstrated by the blood and
ascites culture results in the two sub cohorts stratified by their
CRP profile. Therefore, we hypothesize that abundance of specific
genera must play a prominent role in the induction of systemic
inflammation in cirrhosis. This hypothesis is supported by other
studies where specific bacterial species correlate with clinical
measures (27, 31).
We also identified five bacterial genera that were significantly
different between ascites and blood samples, despite the
small cohort size. Some of these genera were also cultivated
from additional samples of the respective compartments,
Frontiers in Immunology | www.frontiersin.org 8 February 2019 | Volume 10 | Article 69
Alvarez-Silva et al. Inflammation and Microbiome in Cirrhosis
FIGURE 4 | Beta-diversity analysis. Principal coordinate analysis shows clear separation between ascites and peripheral blood samples, but samples do not cluster
based on inflammation status. (A) Unweighted UniFrac (B) Weighted UniFrac.
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FIGURE 5 | Genera differentially abundant among ascites and blood samples.
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TABLE 3 | Differentially abundant genera between ascites and blood.
Kingdom Phylum Class Order Family Genus Padj Sig. log2FC Dir
Bacteria Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Escherichia/Shigella 0.00019243 *** 2.75 Blood
Bacteria Proteobacteria Gammaproteobacteria Pseudomonadales Pseudomonadaceae Pseudomonas 0.00019243 *** 0.74 Blood
Bacteria Proteobacteria Betaproteobacteria Burkholderiales Oxalobacteraceae Janthinobacterium 0.038589035 * −1.04 Ascites
Bacteria Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Serratia 0.038589035 * −2.21 Ascites
Bacteria Proteobacteria Betaproteobacteria Burkholderiales Oxalobacteraceae Rugamonas 0.041897934 * −0.71 Ascites
Padj, adjusted P-value; Sig., significance level; ***P < 0.001, *P < 0.05; Dir, direction of enrichment; log2FC, log2 of fold change.
confirming the viability of at least some of the bacteria
reported in our study. Even though high CRP levels were
associated with SBP, we did not see a significant difference
in microbiome composition between high and low CRP
samples, possibly due to reduced statistical power. However,
the genera Escherichia/Shigella and Janthinobacterium showed
higher abundance in blood samples of patients with systemic
inflammation. Escherichia is already known for its pathogenic
capabilities via lipopolysaccharides binding to Toll-like receptor
4, especially in individuals with dysfunctional immune response.
Janthinobacterium, another Gram-negative bacterium, has not
been described in relation to bacteremia previously, but
could also induce inflammation via the same mechanism. On
the other hand, while relative abundance of Escherichia was
decreased in ascites samples, Janthinobacterium was increased.
We speculate that the compartmentalization of immune
dysfunction might be the reason behind the different behavior
of these two bacteria, both of which are Gram-negative, in the
different compartments.
In decompensated cirrhosis, representative markers of
systemic inflammation and the microbiota seem to be
dysregulated in ascites and blood. While a relationship
between systemic inflammation and the microbiota seems
to exist in blood, this is not found in ascites. These data
may suggest the compartmentalization of the immune
response and its interaction with the microbiome is especially
important and evident in blood, while in ascites not found in
our hands.
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